Subdomains of epidemiological activity classified according to techniques have been shorter-lived than those classified by the type of disease or exposure. Most of us feel comfortable with broad categories defined by disease group (such as 'cancer epidemiology') or by exposure ('nutritional epidemiology'). In the past, brief vogues for terms such as 'biochemical epidemiology' have signalled the availability of new techniques that have been ultimately absorbed into these other entities. Will the term 'molecular epidemiology' suffer this fate, or does it imply a paradigm shift that will establish it as a genuine descriptor of a major subdomain of epidemiological activity?
A MEDLINE search on the term 'molecular epidemiology' reveals over 1600 citations mostly on use of molecular techniques to subtype infectious pathogens. I suspect that infectious disease epidemiologists use the term 'molecular epidemiology' to describe this set of techniques, not a paradigm shift in their science. Similarly, they use the term 'seroepidemiology' to describe studies using the prevalence of serum antibodies in person, place and time to make inferences about the epidemiology of specific infectious diseases. Sprinkled throughout these citations are chronic disease studies, particularly cancer studies, mainly addressing the use of molecular techniques to make improved or novel assessments of exposures, or to define inherited susceptibility. I will address the applications of molecular techniques to cancer epidemiology, assuming that many of the lessons that can be learned apply to the epidemiology other non-infectious diseases.
Exposure Assessment
Even moderate non-differential misclassification of exposure substantially degrades the relative risks observed in welldesigned epidemiological studies, limiting our ability to make causal inferences. Differential misclassification of course, by leading to biased estimates of relative risks can mislead us altogether. Of the molecular methods that offer the prospect of improved exposure classification, DNA adducts and 'DNA fingerprinting' have been the most extensively studied.
DNA adducts
One mechanism by which carcinogens may cause mutations in DNA is by covalently binding to DNA and (if these adducts are not removed) causing a mutation when the DNA is copied during cell division. Measurement of adducts in target tissues obtained by biopsy or at autopsy, or in more readily available surrogate tissues such as white blood cells, can be used to infer exposure to the parent compound of the adduct.
Even before examining the sensitivity and specificity of these measures there are mechanistic limitations to this approach. Before a compound can create a DNA adduct it must be absorbed, and is usually metabolized by enzymes that may differ between individuals due to inherited polymorphic DNA sequence variation or because of upregulation or downregulation of the gene by other external agents. Thus, adduct levels are unlikely ever to be perfectly correlated with exposure. This is a defect if the aim of measuring the adduct is as a surrogate of exposure to the original compound. However, particularly if we do not have good methods for measuring these between-person differences in metabolism, by measuring the 'biologically effective dose' the adduct may be more powerful in defining causal exposures than even a perfect measure of external exposure.
Unfortunately, relatively few clear examples exist of adduct measurement clinching a new exposure-disease relation. Many adducts e.g. benzo[a]pyrene adducts in smokers or those heavily occupationally exposed such as coke-oven workers, are hightech measurements of exposures that can be accurately assessed with a few simple questions such as 'Do you smoke?' or 'What is your occupation?'. As the methods become more sensitive however, they may prove more useful in applications to low-level or insidious exposures such as passive smoking or air pollution.
DNA fingerprinting
There has been much excitement about the possibility that the spectrum of mutations in the DNA of tumours or surrounding tissue may reveal the 'fingerprints' or 'signature' of the relevant carcinogenic agent. There has been at least one substantial success for this concept.
Aflatoxin adducts and liver cancer
The relation of aflatoxin (specifically aflatoxin B 1 ) exposure to primary liver cancer was proposed on the basis of strong evidence from animal experiments and ecological studies that showed geographical correlations between regional per capita aflatoxin exposures and liver cancer rates, particularly in Africa and parts of Asia. Data from analytical epidemiology studies was very hard to interpret however, due to the near-impossibility of measuring exposure to an invisible toxin using interviews or questionnaires, combined with the fact that in many areas with high liver cancer rates the whole population was at least partially exposed. When the very strong relation between hepatitis B carrier status and liver cancer became apparent in many of the same regions with aflatoxin exposure, interest in aflatoxin waned.
Aflatoxin has been resuscitated as a major, and potentially avoidable, liver carcinogen by molecular evidence. First, a high prevalence of characteristic GϾT (guanine to thymidine) mutations in the p53 gene in liver tumours from Africa and China was observed; 1,2 this is the specific mutation that would be expected to result from nucleotide mispairing due to aflatoxin adducts and that had been observed in tumours from animals exposed to aflatoxin. Second, newer sensitive techniques for measuring aflatoxin levels in blood and urine, have permitted longitudinal studies to confirm that higher adduct loads are associated with higher risk of liver cancer in a doseresponse manner, 3 and synergistically interact with hepatitis B carrier status. Trials are now proceeding with Oltipraz, a drug that reduce the metabolic activation of aflatoxin to the DNAdamaging form. It is unlikely that this progress would have been made without the application of these molecular techniques.
It may be no accident however, that it is now several years since these relations were established, and only a few other examples of carcinogens with one-one relations with specific mutational spectra have become apparent. The fact that with only four bases to mutate (A,C,T,G) there is a limited potential repertoire of specific mutations will probably limit this approach to exposure assessment for the thousands of potential carcinogens we are interested in.
Inherited Susceptibility
The other major use of the term 'molecular epidemiology' describes the use of molecular techniques to improve the definition of inherited susceptibility to disease. Previously we have used family history as a poor surrogate for susceptibility, recognizing that family history is likely to be both very insensitive for low-penetrance traits and very non-specific. With the completion of the Human Genome Project between 2000 and 2004 the wild-type (most common) sequence of all 60 000-100 000 human genes will become available. It will be possible to ascertain whether individuals in epidemiological studies carry gene variants that may predispose them to the disease under study.
High-penetrance genes
Much publicity has attended the discovery of genes such as BRCA1 and BRCA2 that, when inherited in a mutated form, convey a lifetime breast cancer risk estimated to be up to 50-85% and cause about 3-8% of all breast cancer. 4 The discoveries of these genes and mutations in genes such as hMSH2 and hMLH1 (colorectal cancer), and p16 (familial melanoma) has clear clinical relevance, and may lead to earlier detection of cancers due to definition of a high-risk group for targeted screening, as well as to therapies that exploit our understanding of the specific molecular defect caused by these mutations. The implications for epidemiologists are more subtle. At least two potential advantages follow if it is possible to genotype participants in an epidemiological study for these mutations.
Firstly stratification of individuals by inherited risk should improve our ability to ascertain 'environmental' exposure-disease relations. The existence in a population of people with a very high inherited risk of a disease will attenuate associations observed between exposures and the disease in the overall population. Removal of these people in an analysis should increase the relative risk observed between exposure and disease. A problem with this argument is that for most common diseases, the proportion due to high-penetrance genes is probably small, suggesting that inclusion of these people in an analysis only has a modest effect on the exposure-outcome relations. At younger ages however, where the proportion of disease due to high-penetrance gene mutations may be high, this stratification may be particularly valuable.
Secondly definition of a genetically susceptible stratum will improve our ability to detect gene-environment interactions. It is self-evident that to define gene-environment interactions the best possible definition of genotype is desirable. The prevalence of high-penetrance gene variants however, tends to be very low e.g. 1/800 unselected Caucasians are estimated to be carriers of BRCA1 mutations, so assembling a large enough group of susceptibles to have statistical power to ascertain interactions for high-penetrance genotypes is problematic.
Low-penetrance genes and 'complex' diseases
The greater than 90% of most chronic diseases not due to inheritance of high-penetrance gene mutations, may or may not be at least partially attributable to inheritance of one or more genes that confer lower degrees of risk. These diseases are sometime called 'complex', because they are not inherited as readily ascertainable single-gene 'simple' Mendelian traits (e.g. dominant, recessive, X-linked), and because they involve interactions with environmental factors and/or co-inheritance of variants in multiple genes.
It is important to note that for most diseases, the existence of low-penetrance gene variants is still a hypothesis. The identification and confirmation of these variants is difficult. Conventional chromosome mapping of the location of highpenetrance genes has relied on collection of DNA from families in which the condition occurs frequently, and subsequent analysis of the chromosomal regions that are consistently inherited by the affected family members but not by those unaffected. These techniques are much less powerful where family members who have co-inherited the same gene mutation may not display the disease phenotype because of lowpenetrance of the mutation. With the imminent availability of the DNA sequence of all genes, combined with newer techniques for high-throughput genotyping of variants, the 'candidate gene' approach is increasingly common. In this approach the prevalence of specific variants in one gene or many genes are compared in cases and controls.
This type of study will present a major challenge to epidemiologists and guarantee continued life for the 'multiple comparisons' debate. With the advent of DNA chip technology we will be able to simultaneously genotype several variants in each of 100 or more potential candidate genes; the potential for chance false positive results will be very high. On the other hand, conventional multiple comparisons 'corrections' that reduce P-values to much less than the nominal 0.05 level will, when we expect effects of low-penetrance genes to be weak, virtually guarantee false negative results. One conventional response is to include in studies only 'sensible' candidate genes for which a biologically plausible mechanism can be proposed by which a variant in the gene would affect risk of the disease under study. Unfortunately, recent experience suggests that there are many mechanistic surprises in store: who would have wagered on a lipid-metabolism gene (ApoE) being related to Alzheimer's Disease, 5 or an antioxidant gene (SOD) causing familial amyotrophic lateral sclerosis? 6 The use of split-half designs to attempt to validate unexpected findings is worth considering. However, these approaches will be limited by the fact that sample sizes are likely to be inadequate, particularly THE FUTURE OF MOLECULAR EPIDEMIOLOGY S1013 for less common genetic variants. We can do what we can to maximize the validity of these studies, but there seems little alternative to a substantial period of uncertainty as we sort through these candidates.
Gene-environment interactions
If data on environmental factors are available in these studies then gene-environment interactions can be assessed. This will exacerbate the 'multiple comparisons' problem, as there are so many environmental variables that could be interacted with genetic information in a typical study. A further problem is familiar to anyone who has ever done a power calculation for sample size to detect a modest interaction-these studies will have to be large, of the order of 1000 or more cases.
These challenges suggest that the rules of causal inference in studies using these new techniques will be little different from those used currently. We will need consistency of associations across multiple, large, well-done studies, combined with biological plausibility (when available) and an absence of apparent confounders, before we will feel confident making causal statements when relative risks are modest.
A return to environmental exposure
One of the most difficult problems for environmental epidemiologists is that humans are rarely exposed to isolated chemical compounds, but are usually exposed to complex mixtures of hundreds of different compounds in diet, air pollution, or at the workplace. Teasing out by conventional exposure assessment the true causative 'bad actors' from these mixtures may be literally impossible if exposures to the compounds are highly correlated. Here, it is possible that genetic studies may offer a way out: the finding that a particular variant in a metabolism gene consistently increases the risk of disease associated with a specific exposure would strongly implicate the substrates of that gene as the causative chemicals. In this way, information on susceptibility may permit us to infer which compounds in the complex mixture of exposures are most relevant to disease causation.
Ethical Issues
Unlike most environmental exposures that can be altered if proven to cause disease, inherited gene variants cannot be changed, and can be passed on to subsequent generations. Much of the existing experience in genetic counselling has addressed issues of reproductive decision-making in the context of relatively uncommon but severe conditions such as Huntington's Disease or cystic fibrosis. There is much less experience in counselling children or adults about risks of late-onset chronic diseases, and even less about counselling for modest increments in risk. Add to this uncertainty about the magnitude of these risks that we will face due to the problems outlined above, plus the sheer amount of information on many dozens of genes that some studies will generate, and the complexities of epidemiological analysis seem almost trivial next to the ethical issues of whether or not to provide results to study participants, and if so, how to do it. The problem of whether or not to counsel is greatly magnified in countries such as the US in which loss of health insurance could result from knowledge of genetic information. Even in countries without this specific problem however, access to life insurance or denial of employment may be compromised, and the psychological impact of genetic knowledge must be considered. And it is not just individuals who are at risk. The Eugenics movements, and plain old uninformed public opinion, have stereotyped and discriminated against segments of populations in the past because of real or imagined genetic differences. There is no reason to think that this cannot happen again just because our tools for defining genetic variation are hi-tech. A natural response to these dangers is to try and prevent the research from happening, but this particular genie is out of the bottle and a more rational response is to follow established rules of human subject research to minimize the risks to research participants and maximize the potential benefits to society.
Why Put the 'Molecular' in 'Molecular Epidemiology'?
After this somewhat sombre tour of the landscape, one might be entitled to ask whether these developments will be good for the future of epidemiology? The answer remains to be seen, but there is no doubt that molecular techniques and the human gene sequence will be key inputs into future epidemiological studies. The only guarantee we have is that insights will emerge from entirely unexpected directions, and that the identification of genetic variants that alter disease risk will provide clues to new biological pathways to disease. Under these circumstances we need to reinvent at least some aspects of the discipline and train future epidemiologists to be able to take appropriate advantage of these techniques.
Will there be something called 'molecular epidemiology' in 20 years time? Perhaps the best result would be 'No'; this would imply that the molecular techniques have been so thoroughly incorporated into the conventional subdomains of epidemiology that there is no reason to define a separate branch. Meanwhile however, we are faced with the challenge of revising the way at least some of us practice our discipline. If only to provide an organizing principle for training, coursework, funding, and methods development, the term 'molecular epidemiology' is a useful one and has a future. The future of the science of epidemiology however, lies in defining the best use of these molecular techniques, and ensuring these techniques do not define our science.
